39 results
8-K
TVTX
Travere Therapeutics Inc
4 Dec 23
Cost Associated with Exit or Disposal Activities
4:10pm
engagement with the FDA on focal segmental glomerulosclerosis (FSGS), the Company also provided an update that the two-year results from the Phase 3 DUPLEX
8-K
EX-99.1
TVTX
Travere Therapeutics Inc
7 Nov 23
Travere Therapeutics Reports Third Quarter 2023 Financial Results
4:04pm
prescribers. Furthermore, our payer engagement efforts have resulted in broadening high-quality access and we made enhancements to our Travere Total
8-K
iflnk
21 Sep 23
Other Events
7:35am
8-K
EX-99.1
ttjulj
3 Aug 23
Travere Therapeutics Reports Second Quarter 2023 Financial Results
4:06pm
8-K
EX-10.1
i30kai85o2
17 Jul 23
Entry into a Material Definitive Agreement
8:07am
8-K
w3r7i8zbzzhuuhwd
31 May 23
Other Events
4:57pm
8-K
9h3f 0pu9ylio3
12 Apr 23
Changes in Registrant's Certifying Accountant
4:30pm
8-K/A
xudbqqf3
17 Aug 22
Departure of Directors or Certain Officers
5:20pm
8-K
EX-99.1
a1nb9rt
5 May 22
Travere Therapeutics Reports First Quarter 2022 Financial Results
12:00am
8-K
tweg7uy3 gen2i4fufjr
20 Apr 22
Departure of Directors or Certain Officers
4:41pm
8-K
EX-99.1
ikvf22xf i5h2z1x
10 Jan 22
Travere Therapeutics Provides Corporate Update and 2022 Outlook
7:08am